NYSE:COO

Stock Analysis Report

Executive Summary

The Cooper Companies, Inc. operates as a medical device company worldwide.

Snowflake

Solid track record with mediocre balance sheet.


Similar Companies

Share Price & News

How has Cooper Companies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: COO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.6%

COO

3.2%

US Medical Equipment

0.7%

US Market


1 Year Return

13.9%

COO

19.2%

US Medical Equipment

12.9%

US Market

Return vs Industry: COO underperformed the US Medical Equipment industry which returned 19.2% over the past year.

Return vs Market: COO exceeded the US Market which returned 12.9% over the past year.


Shareholder returns

COOIndustryMarket
7 Day3.6%3.2%0.7%
30 Day3.3%4.0%4.4%
90 Day-10.0%3.3%7.0%
1 Year14.0%13.9%20.2%19.2%15.4%12.9%
3 Year75.7%75.6%86.0%80.3%49.1%39.5%
5 Year80.9%80.7%120.3%96.3%62.7%44.7%

Price Volatility Vs. Market

How volatile is Cooper Companies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cooper Companies undervalued compared to its fair value and its price relative to the market?

5.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: COO ($301.98) is trading below our estimate of fair value ($320.43)

Significantly Below Fair Value: COO is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: COO is good value based on its PE Ratio (33.4x) compared to the Medical Equipment industry average (46.5x).

PE vs Market: COO is poor value based on its PE Ratio (33.4x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: COO is poor value based on its PEG Ratio (2.4x)


Price to Book Ratio

PB vs Industry: COO is overvalued based on its PB Ratio (4.1x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Cooper Companies forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

14.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COO's forecast earnings growth (14% per year) is above the savings rate (2.7%).

Earnings vs Market: COO's earnings (14% per year) are forecast to grow slower than the US market (14.4% per year).

High Growth Earnings: COO's earnings are forecast to grow, but not significantly.

Revenue vs Market: COO's revenue (6.2% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: COO's revenue (6.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COO's Return on Equity is forecast to be low in 3 years time (15%).


Next Steps

Past Performance

How has Cooper Companies performed over the past 5 years?

5.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COO has high quality earnings.

Growing Profit Margin: COO's current net profit margins (17.1%) are higher than last year (5.2%).


Past Earnings Growth Analysis

Earnings Trend: COO's earnings have grown by 5.8% per year over the past 5 years.

Accelerating Growth: COO's earnings growth over the past year (249.3%) exceeds its 5-year average (5.8% per year).

Earnings vs Industry: COO earnings growth over the past year (249.3%) exceeded the Medical Equipment industry 28.3%.


Return on Equity

High ROE: COO's Return on Equity (12.3%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cooper Companies's financial position?


Financial Position Analysis

Short Term Liabilities: COO's short term assets ($1.2B) exceeds its short term liabilities ($889.4M)

Long Term Liabilities: COO's short term assets (1.2B) do not cover its long term liabilities (1.7B)


Debt to Equity History and Analysis

Debt Level: COO's debt to equity ratio (50.1%) is considered high

Reducing Debt: COO's debt to equity ratio has increased from 13.4% to 50.1% over the past 5 years.

Debt Coverage: COO's debt is well covered by operating cash flow (41.4%).

Interest Coverage: COO's interest payments on its debt are well covered by EBIT (6.5x coverage).


Balance Sheet

Inventory Level: COO has a high level of physical assets or inventory.

Debt Coverage by Assets: COO's debt is not covered by short term assets (assets are 0.6x debt).


Next Steps

Dividend

What is Cooper Companies's current dividend yield, its reliability and sustainability?

0.02%

Current Dividend Yield


Dividend Yield vs Market

company0.02%marketbottom25%1.4%markettop25%3.6%industryaverage1.2%forecastin3Years0.02%

Current dividend yield vs market & industry

Notable Dividend: COO's dividend (0.02%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.42%).

High Dividend: COO's dividend (0.02%) is low compared to the top 25% of dividend payers in the US market (3.65%).


Stability and Growth of Payments

Stable Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: COO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: COO is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cooper Companies's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Albert White (49yo)

1.5yrs

Tenure

US$6,067,120

Compensation

Mr. Albert G. White, III, has been President, Director and Chief Executive Officer of The Cooper Companies since May 1, 2018. Mr. White served as Chief Financial Officer of The Cooper Companies Inc. since  ...


CEO Compensation Analysis

Compensation vs Market: Albert's total compensation ($USD6.07M) is below average for companies of similar size in the US market ($USD11.01M).

Compensation vs Earnings: Albert's compensation has increased by more than 20% in the past year.


Management Age and Tenure

1.7yrs

Average Tenure

52yo

Average Age

Experienced Management: COO's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Age and Tenure

13.8yrs

Average Tenure

72yo

Average Age

Experienced Board: COO's board of directors are seasoned and experienced ( 13.8 years average tenure).


Insider Trading

Insider Buying: COO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$551,47713 Sep 19
Allan Rubenstein
EntityIndividual
Role
Vice Chairman
Vice Chairman & Lead Director
Shares1,835
Max PriceUS$303.00
SellUS$378,69719 Jun 19
Randal Golden
EntityIndividual
Role
Chief Legal Officer
VP, General Counsel & Secretary
Shares1,154
Max PriceUS$328.16
SellUS$114,99219 Jun 19
Gary Petersmeyer
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares355
Max PriceUS$323.92
SellUS$871,94823 May 19
Jody Lindell
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,943
Max PriceUS$296.80
SellUS$710,72202 Apr 19
Agostino Ricupati
EntityIndividual
Role
Chief Accounting Officer
Senior VP of Finance & Tax and Chief Accounting Officer
Shares2,400
Max PriceUS$296.14
SellUS$483,32527 Mar 19
Brian Andrews
EntityIndividual
Role
Chief Financial Officer
Senior VP
Shares1,648
Max PriceUS$293.28
SellUS$663,92614 Mar 19
Robert Auerbach
EntityIndividual
Role
Unit President
President of Coopersurgical Inc
Shares2,272
Max PriceUS$292.22
SellUS$229,21712 Mar 19
Gary Petersmeyer
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares799
Max PriceUS$286.88
SellUS$1,030,12112 Mar 19
Michael Kalkstein
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,570
Max PriceUS$288.55
BuyUS$84,07512 Dec 18
Allan Rubenstein
EntityIndividual
Role
Vice Chairman
Vice Chairman & Lead Director
Shares348
Max PriceUS$241.60

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Albert White (49yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$6.07m
  • Dan McBride (55yo)

    Executive VP & COO

    • Tenure: 6yrs
    • Compensation: US$3.83m
  • Bob Auerbach (58yo)

    President of Coopersurgical Inc

    • Tenure: 1.6yrs
    • Compensation: US$1.47m
  • Kim Duncan

    Vice President of Investor Relations & Administration

    • Tenure: 0yrs
  • Brian Andrews (40yo)

    Senior VP

    • Tenure: 1.5yrs
    • Compensation: US$1.20m
  • Randy Golden (57yo)

    VP, General Counsel & Secretary

    • Tenure: 5.8yrs
  • Agostino Ricupati (52yo)

    Senior VP of Finance & Tax and Chief Accounting Officer

    • Tenure: 2.1yrs
    • Compensation: US$1.21m
  • Holly Sheffield (48yo)

    Executive VP & Chief Strategy Officer

    • Tenure: 1.4yrs
    • Compensation: US$2.59m
  • Juan Aragón

    President of CooperVision Specialty EyeCare Division

    • Tenure: 1.8yrs

Board Members

  • Allan Rubenstein (74yo)

    Vice Chairman & Lead Director

    • Tenure: 17.3yrs
    • Compensation: US$378.47k
  • Tom Bender (80yo)

    Independent Chairman

    • Tenure: 17.3yrs
    • Compensation: US$491.57k
  • Robert Weiss (72yo)

    Non-Independent Director

    • Tenure: 23.8yrs
    • Compensation: US$6.40m
  • Michael Kalkstein (76yo)

    Independent Director

    • Tenure: 27.8yrs
    • Compensation: US$380.09k
  • Bill Kozy (67yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$357.59k
  • Gary Petersmeyer (72yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$364.09k
  • Jody Lindell (68yo)

    Independent Director

    • Tenure: 13.8yrs
    • Compensation: US$378.09k
  • Albert White (49yo)

    President

    • Tenure: 1.5yrs
    • Compensation: US$6.07m
  • Colleen Jay (56yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$362.09k

Company Information

The Cooper Companies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: The Cooper Companies, Inc.
  • Ticker: COO
  • Exchange: NYSE
  • Founded: 1980
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$14.970b
  • Shares outstanding: 49.57m
  • Website: https://www.coopercos.com

Number of Employees


Location

  • The Cooper Companies, Inc.
  • 6140 Stoneridge Mall Road
  • Suite 590
  • Pleasanton
  • California
  • 94588
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
COONYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1983
CP6DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1983
COO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1983
0I3ILSE (London Stock Exchange)YesCommon StockGBUSDJan 1983

Biography

The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of con ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 23:34
End of Day Share Price2019/11/15 00:00
Earnings2019/07/31
Annual Earnings2018/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.